Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8789579 | 1.00 | CES2 (0.38) | CES2CES1EPHX1ALDH1A1EPHX2 | |
| SCHEMBL2142264 | 1.00 | CES2 (0.38) | CES2CES1EPHX1ALDH1A1EPHX2 | |
| SCHEMBL11956974 | 0.97 | — | — | |
| SCHEMBL14294174 | 0.86 | — | — | |
| SCHEMBL16935671 | 0.78 | TSHR (0.35) | EPHX1SMN1; SMN2MAPTKDM4ECYP3A4 | |
| SCHEMBL16935672 | 0.78 | TSHR (0.35) | EPHX1SMN1; SMN2MAPTKDM4ECYP3A4 | |
| SCHEMBL11670331 | 0.78 | TSHR (0.35) | TSHR | |
| SCHEMBL3075371 | 0.78 | CES2 (0.41) | CES2CES1EPHX1ALDH1A1EPHX2 | |
| SCHEMBL30510609 | 0.77 | — | — | |
| SCHEMBL172020 | 0.77 | CES2 (0.32) | CES2CES1EPHX1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728207-B1 | QUINAZOLINONES AS PARP14 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20230018702-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2023-01-19 | — | — | US | disclosed |
| US-11008308-B2 | Quinazolinones as PARP14 inhibitors | Ribon Therapeutics Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200247788-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2020-08-06 | — | — | US | disclosed |
| US-10562891-B2 | Quinazolinones as PARP14 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190194174-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2019-06-27 | — | — | US | disclosed |
| EP-0788796-A1 | URICOSURIC AGENT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247788-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | CES2 4158/4885CES1 3319/4885EPHX1 4018/4885 |
| US-10562891-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | CES2 4158/4885CES1 3319/4885EPHX1 4018/4885 |
| US-11008308-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | CES2 4158/4885CES1 3319/4885EPHX1 4018/4885 |
| US-20230018702-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | CES2 4158/4885CES1 3319/4885EPHX1 4018/4885 |
| US-20190194174-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | CES2 4158/4885CES1 3319/4885EPHX1 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.